American biopharmaceutical company AbbVie has opened a new €23m European manufacturing services hub in Clonshaugh, North Dublin, Ireland.
The site is spread across two sites within the IDA (Investment Development Agency) Business Park in Clonshaugh.
According to AbbVie, the facility will serve as an international base for a line of supply chain, production and engineering services in order to aid the firm’s international network.
The new services hub is expected to assist Irish manufacturing facilities and business operations in other European nations, including Germany, Italy, and the Netherlands.
The establishment of the new centre shows Ireland’s strategic significance within AbbVie’s global footprint.
AbbVie began manufacturing in Ireland in 1974 and now has sizable operations in six different Irish cities, including Cork, Sligo, Mayo, and Dublin. The expanded Clonshaugh site is anticipated to employ around 400 people.
AbbVie EVP chief operations officer Azita Saleki-Gerhardt said: “Our new AbbVie North Dublin (AND) facility will be a key node in AbbVie’s global Operations network, serving as a European hub bringing together our Dublin-based supply chain, engineering, quality assurance and manufacturing teams for the first time.
“Built with our employees and the future in mind, AbbVie North Dublin features new, improved collaboration spaces and amenities designed to significantly elevate our employees’ experiences and make this facility a great place to work for many years to come.”
The biopharmaceutical firm, which was established in 2013 following a split from Abbott, has continuously and sizably invested in Ireland over the previous 10 years. In 2020, it acquired Allergan and its Irish operations.
With the new opening, AbbVie has invested more than €430m in Ireland over the previous 10 years, following a €60m investment in Cork last year.
IDA Ireland CEO Michael Lohan said: “The opening of this new European Services hub is a wonderful addition to the six locations across Ireland that AbbVie currently operates in. This is a continued endorsement in Ireland as a strategic location for biopharmaceutical investment and one we are very proud of.”
